Clinical factors at rebiopsy in all patients and patients with r-PET analysis
| . | All rebiopsies (N = 397) . | Rebiopsies with r-PET analysis (N = 290) . |
|---|---|---|
| Diagnosis to rebiopsy >5 y | 143 (36%) | 107 (37%) |
| History of composite/transformed histology | 39 (10%) | 27 (9%) |
| Any treatment | 361 (91%) | 270 (93%) |
| Last treatment to rebiopsy >6 mo | 218/361 (60%) | 156/270 (58%) |
| Response to most recent treatment based on most recent prior imaging | ||
| Complete remission | 260/361 (72%) | 114/270 (42%) |
| Noncomplete remission∗ | 101/361 (28%) | 156/270 (58%) |
| Clinical factors at time of rebiopsy | ||
| Palpable lymphadenopathy† | 168/385(44%) | 118/283 (41%) |
| B symptoms† | 38/388 (10%) | 31/287 (11%) |
| Elevated LDH† | 110/276 (40%) | 88/212 (42%) |
| Extranodal disease† | 214/372 (58%) | 179 (62%) |
| New site of disease compared to most recent prior imaging† | 206/308 (67%) | 167/243 (58%) |
| >1 site of suspected disease | 262 (66%) | 217 (77%) |
| r-PET DS (4-5) | NA | 265 (91%) |
| Rebiopsy site was most FDG-avid site‡ | NA | 151/280 (54%) |
| . | All rebiopsies (N = 397) . | Rebiopsies with r-PET analysis (N = 290) . |
|---|---|---|
| Diagnosis to rebiopsy >5 y | 143 (36%) | 107 (37%) |
| History of composite/transformed histology | 39 (10%) | 27 (9%) |
| Any treatment | 361 (91%) | 270 (93%) |
| Last treatment to rebiopsy >6 mo | 218/361 (60%) | 156/270 (58%) |
| Response to most recent treatment based on most recent prior imaging | ||
| Complete remission | 260/361 (72%) | 114/270 (42%) |
| Noncomplete remission∗ | 101/361 (28%) | 156/270 (58%) |
| Clinical factors at time of rebiopsy | ||
| Palpable lymphadenopathy† | 168/385(44%) | 118/283 (41%) |
| B symptoms† | 38/388 (10%) | 31/287 (11%) |
| Elevated LDH† | 110/276 (40%) | 88/212 (42%) |
| Extranodal disease† | 214/372 (58%) | 179 (62%) |
| New site of disease compared to most recent prior imaging† | 206/308 (67%) | 167/243 (58%) |
| >1 site of suspected disease | 262 (66%) | 217 (77%) |
| r-PET DS (4-5) | NA | 265 (91%) |
| Rebiopsy site was most FDG-avid site‡ | NA | 151/280 (54%) |